Sarcoidosis Overview

Sarcoidosis is a multisystem disorder of unknown etiology characterized by the presence of non-caseating granulomas in organs. This condition mostly affects young adults and characteristically presents with reticular opacities in the lungs and bilateral hilar lymphadenopathy. Other involved sites include eyes, skin, and joints, and in some cases, the reticuloendothelial system, musculoskeletal system, exocrine glands, heart, kidney, and central nervous system.

“Sarcoidosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sarcoidosis Market.

The Sarcoidosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Sarcoidosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Sarcoidosis treatment therapies with a considerable amount of success over the years. Sarcoidosis Key players such as – Foresee Pharmaceuticals, AI Therapeutics, Molecure, Xentria, Inc., Kinevant Sciences, Novartis, aTyr Pharma, and others, are developing therapies for the Sarcoidosis treatment 

• Sarcoidosis Emerging therapies such as – FP-020, LAM001, OATD-01, XTMAB-16, Namilumab, CMK389, Efzofitimod, and others are expected to have a significant impact on the Sarcoidosis market in the coming years.   
• In August 2022, the Food and Drug Administration (FDA) granted Fast Track designation to efzofitimod(ATYR1923) for treatment of pulmonary sarcoidosis. Efzofitimod has also received FDA orphan drug designation for the treatment of sarcoidosis
• In September 2022, aTyr Pharma initiated a multicenter, randomized, double-blind, placebo controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versusplacebo after 48 weeks of treatment

Route of Administration

Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Sarcoidosis Pipeline Therapeutics Assessment

• Sarcoidosis Assessment by Product Type
• Sarcoidosis By Stage and Product Type
• Sarcoidosis Assessment by Route of Administration
• Sarcoidosis By Stage and Route of Administration
• Sarcoidosis Assessment by Molecule Type
• Sarcoidosis by Stage and Molecule Type

DelveInsight’s Sarcoidosis Report covers around 15+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Sarcoidosis Therapeutics Market include:

Key companies developing therapies for Sarcoidosis are – Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Antares Pharma Inc., Apotex Inc., Azurity Pharmaceuticals Inc., Cadila Healthcare Ltd., Dr. Reddys Laboratories Ltd., Fresenius SE and Co. KGaA, Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Intas Pharmaceuticals Ltd., Mallinckrodt Plc, Medexus Pharmaceuticals Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson and Johnson Inc. Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Antares Pharma Inc., Apotex Inc., Azurity Pharmaceuticals Inc., Cadila Healthcare Ltd., Dr. Reddys Laboratories Ltd., Fresenius SE and Co. KGaA, Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Intas Pharmaceuticals Ltd., Mallinckrodt Plc, Medexus Pharmaceuticals Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson and Johnson Inc., and others.

Emerging Sarcoidosis Drugs Under Different Phases of Clinical Development Include:

• FP-020: Foresee Pharmaceuticals
• LAM001: AI Therapeutics
• OATD-01: Molecure
• XTMAB-16: Xentria, Inc
• Namilumab: Kinevant Sciences
• CMK389: Novartis
• Efzofitimod: aTyr Pharma

Get a Free Sample PDF Report to know more about Sarcoidosis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight

Sarcoidosis Pipeline Analysis:

The Sarcoidosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Sarcoidosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcoidosis Treatment.
• Sarcoidosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sarcoidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcoidosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Sarcoidosis product details are provided in the report. Download the Sarcoidosis pipeline report to learn more about the emerging Sarcoidosis therapies

Sarcoidosis Pipeline Market Drivers

• Strategic alliances between the Pharmaceutical companies and universities
• Extensive research undertaking and funding

Sarcoidosis Pipeline Market Barriers

• Side-effects associated with the treatment of Sarcoidosis
• Lack of awareness among people in developing countries

Scope of Sarcoidosis Pipeline Drug Insight    

• Coverage: Global
• Key Sarcoidosis Companies: Foresee Pharmaceuticals, AI Therapeutics, Molecure, Xentria, Inc., Kinevant Sciences, Novartis, aTyr Pharma, and others
• Key Sarcoidosis Therapies: FP-020, LAM001, OATD-01, XTMAB-16, Namilumab, CMK389, Efzofitimod, and others
• Sarcoidosis Therapeutic Assessment: Sarcoidosis current marketed and Sarcoidosis emerging therapies
• Sarcoidosis Market Dynamics: Sarcoidosis market drivers and Sarcoidosis market barriers 

Request for Sample PDF Report for Sarcoidosis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Sarcoidosis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis